Abstracts Archive - Page 1615 of 2425 - ACR Meeting Abstracts

Abstract Number: 2970 • 2016 ACR/ARHP Annual Meeting
Incidence and Characteristics of Vasculitis Associated with Monoclonal Antibodies and Peptide Fusion Proteins: A Survey from the French National Pharmacovigilance Database
Bertrand Lioger^1,2, Fanny Hennekinne¹, Marie-Sara Agier³, Annie-Pierre Jonville-Bera^3,4 and François Maillot^1,5, ¹Internal Medicine, Tours University Hospital, Tours, France, ²GICC UMR 7292, University François Rabelais, Tours, France, ³Clinical Pharmacology, Tours University Hospital, Tours, France, ⁴Regional Pharmacovigilance Center, Tours University Hospital, Tours, France, ⁵INSERM U1069, University François Rabelais, Tours, France
Background/Purpose: Immunological classes of adverse events (AEs), including the immune related AEs and the paradoxical effects, have emerged with the used of biologics. Among them,…
Abstract Number: 2971 • 2016 ACR/ARHP Annual Meeting
Characteristics and Management of IgA Vasculitis (Henoch-Schönlein purpura) in Adults: Data from the 260 Patients Included in the Igavas Survey
Alexandra Audemard-Verger¹, Evangeline Pillebout², Agnès Dechartres³, Johan Chanal⁴, Zahir Amoura⁵, Noemie Le Gouellec⁶, Patrice Cacoub⁷, Noémie Jourde-Chiche⁸, Geoffroy Urbanski⁹, Jean-Francois Augusto⁹, Guillaume Moulis¹⁰, Loic Raffray¹¹, Alban Deroux¹², Aurélie Hummel¹³, Bertrand Lioger¹⁴, Melanie Catroux¹⁵, Stanislas Faguer¹⁶, Julie Goutte¹⁷, Nihal Martis¹⁸, Francois Maurier¹⁹, Etienne Riviere²⁰, Sébastien Sanges²¹, Aurélie Baldolli²², Nathalie Costedoat-Chalumeau²³, Melanie Roriz²⁴, Xavier Puéchal²⁵, Marc Andre²⁶, Christian Lavigne²⁷, Boris Bienvenu²⁸, Arsène Mékinian²⁹, Elie Zagdoun³⁰, Charlotte Girard³¹, Alice Berezne³², Loïc Guillevin²⁵, Eric Thervet³³ and Benjamin Terrier³⁴, ¹Internal Medicine, Caen, France, ²Nephrology, Saint Louis, Paris, France, ³Epidemiology, Hotel Dieu, Paris, France, ⁴Dermatology, Cochin Hospital, Paris, France, ⁵Department of Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ⁶Internal Medicine, Lille, France, ⁷Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Pitié-Salpêtrière, Département de Médecine Interne et d’Immunologie clinique, DHU i2B, Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France, ⁸Vascular Research Center of Marseille, Aix-Marseille Univ., Vascular Research Center of Marseille, Marseille, France, ⁹Internal Medicine, CHU, Angers, France, ¹⁰CHU Purpan, Toulouse, France, ¹¹Internal Medicine, CHU de Bordeaux, Bordeaux, France, ¹²Internal Medicine, CHU Grenoble, Grenoble, France, ¹³Necker, paris, France, ¹⁴GICC UMR 7292, University François Rabelais, Tours, France, ¹⁵Internal Medicine, Cochin Hospital, Paris, France, ¹⁶Nephrology, CHU, Toulouse, France, ¹⁷Internal Medicine, CHU, Paris, France, ¹⁸Internal Medicine, CHU, Nice, France, ¹⁹Department of Internal Medicine, HP Metz Belle Isle Hospital, Metz, France, ²⁰Internal Medicine, CHU, Bordeaux, France, ²¹Université Lille Nord de France, Faculté de Médecine Henri Warembourg, Lille, Lille, France, ²²Internal Medicine, CHU, Caen, France, ²³Internal Medicine, Cochin University Hospital, Paris, France, ²⁴internal Medicine, Lariboisière, Paris, France, ²⁵Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ²⁶Internal Medicine CHU G Montpied, Internal Medicine, Clermont Ferrand, France, ²⁷CHU Angers, department of Internal Medicine, Angers, France, ²⁸Caen University Hospital, Caen, France, ²⁹Service de médecine interne. Hôpital Saint-Antoine., Paris, France, ³⁰Internal Medicine, CH, Saint-Lo, France, ³¹Internal Medicine, CHU, Lyon, France, ³²Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ³³Nephrology, Hopital Européen Georges Pompidou, APHP, PARIS, France, ³⁴National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: We analyzed data from 260 patients with IgAV included in a French multicenter retrospective IGAVAS survey. Results: Mean age at diagnosis was 50.1±18 years,…
Abstract Number: 2972 • 2016 ACR/ARHP Annual Meeting
Vaccination and Risk of Childhood IgA Vasculitis (Henoch–Schönlein): A Case-Crossover Analysis
Maryam Piram¹, Fouad Madhi², Tim Ulinski³ and Alfred Mahr⁴, ¹Pediatrics, Hospital Bicêtre, Kremlin-Bicêtre, France, ²Pediatrics, Centre hospitalier intercommunal Créteil (CHIC), Créteil, France, ³Pediatric Nephrology, Hospital Trousseau, Paris, France, ⁴Internal Medicine, Hospital Saint-Louis, Paris, France
Background/Purpose: The etiology of IgA vasculitis (Henoch–Schönlein, IgAV), the most common systemic vasculitis in children, is unknown, although seasonality in disease onset and clinical observation…
Abstract Number: 2973 • 2016 ACR/ARHP Annual Meeting
A Comparison of Caregiving Burden and Impact in Systemic Vasculitis Versus Other Conditions
Matthew Gray¹, Delesha M. Carpenter², Lorie L. Geryk³, Courtney A. Roberts⁴, Joshua M. Thorpe⁵, Tao Jiang⁵, Susan L Hogan⁶ and Carolyn T. Thorpe⁵, ¹University of Pittsburgh, Pittsburgh, PA, ²Division of Pharmaceutical Outcomes and Policy, University of North Carolina, Asheville, NC, ³Division of Pharmaceutical Outcomes and Policy, University of North Carolina, Chapel Hill, NC, ⁴Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, ⁵School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, ⁶UNC Kidney Center, Chapel Hill, NC
Background/Purpose: Serving as an informal caregiver to a family member or friend with a chronic illness is associated with stress, reduced health status, and financial…
Abstract Number: 2974 • 2016 ACR/ARHP Annual Meeting
An Outcome Survey of 100 Patients with Cerebral Venous Sinus Thrombosis Due to Behcet’s Syndrome Followed up at a Single, Dedicated Center
Enes Ali Kurt¹, Naci Kocer², Yesim Ozguler¹, Didar Ucar³, Ugur Uygunoglu⁴, Civan Islak⁵, Sebahattin Saip⁴, Melike Melikoglu¹, Vedat Hamuryudan¹, Yilmaz Ozyazgan³, Sebahattin Yurdakul¹, Aksel Siva⁴, Hasan Yazici¹ and Emire Seyahi¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Department of Neuroradiology, Istanbul University, Cerrahpasa Medical Faculty, Department of Neuroradiology, Istanbul, Turkey, ³Ophthalmology, Istanbul University, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey, ⁴Department of Neurology, Istanbul University, Cerrahpasa Medical Faculty, Department of Neurology, Istanbul, Turkey, ⁵Department of Neuroradiology, Istanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey
Background/Purpose: Methods: We identified 100 (81 M/19 F) patients with BS who were diagnosed as having CVST. All contacted were called back to the…
Abstract Number: 2975 • 2016 ACR/ARHP Annual Meeting
Increase of Sacroiliitis By Follow-up and Routine CT in Patients with Behcet’s Disease
Qianqian Chen¹, Junxia Li¹, Chong Gao², Hongyan Wen³ and Xiaofeng Li³, ¹The Second Hospital of Shanxi Medical University, Taiyuan, China, ²Department of Pathology, Joint Program in Transfusion Medicine, Brigham and Women’s Hospital/Children’s Hospital Boston, Harvard Medical School, Boston, MA, Cambridge, MA, ³Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, China
Background/Purpose: Widely various frequencies of sacroiliitis or spondylitis have been reported in different regions of patients with Behcet’s Disease (BD). Although BD is also called…
Abstract Number: 2976 • 2016 ACR/ARHP Annual Meeting
Disease Flares and Persistent Low-Level of Disease: Long-Term Outcome in a Cohort of Patients with BehçEt’s Disease
Elena Elefante¹, Rosaria Talarico¹, Anna d'Ascanio², Rossella Neri¹, Chiara Stagnaro², Chiara Tani², Chiara Baldini² and Marta Mosca², ¹RHEUMATOLOGY UNIT, University of Pisa, Pisa, Italy, ²Rheumatology Unit, University of Pisa, Pisa, Italy
Background/Purpose: Behçet's disease (BD) is a multisystemic, chronic relapsing inflammatory disease classified among the vasculitis. Neurological and eye involvement are two of the most serious…
Abstract Number: 2977 • 2016 ACR/ARHP Annual Meeting
Treatment of Cryoglobulinemic Vasculitis with Sofosbuvir in Four Combination Protocols
Mohamed Tharwat Hegazy¹, Mohamed A Hussein¹, Luca Quartuccio², Mary Fawzy¹, Naguib Zoheir³, Mona I. Ellawindi⁴, Milena Bond², Cesare Mazzaro⁵, Ahmed El Ray⁶, Maissa El Said El Raziky^7,8, Magdy El Serafy⁹, Wahid Doss⁹, Patrice Cacoub¹⁰, Loïc Guillevin¹¹, Salvatore De Vita², Sherif El Khamisy¹² and Gaafar Ragab¹, ¹Internal Medicine, Internal Medicine Department, Rheumatology and Clinical Immunology Unit, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, ²Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, Udine, Italy, ³Clinical and Chemical Pathology Department, Clinical and Chemical Pathology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, ⁴Community Medicine, Community Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, ⁵Internal Medicine, Pordenone Hospital, Italy, pordenone, Italy, ⁶Theodor Bilharz Research Institute, Cairo, Egypt, Cairo, Egypt, ⁷Fatimid Cairo hospital, Cairo, Egypt, Cairo, Egypt, ⁸Tropical Medicine, Tropical Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt, cairo, Egypt, ⁹Tropical Medicine, Tropical Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt, Cairo, Egypt, ¹⁰Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France, ¹¹Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ¹²Zewail city of Science and Technology, Egypt, Giza, Egypt
Background/Purpose: Cryoglobulinemic Vasculitis (CV) is a systemic vasculitis affecting small and medium-sized vessels. Following emergence of direct acting antiviral drugs, which paved the way to…
Abstract Number: 2978 • 2016 ACR/ARHP Annual Meeting
Psychiatric Involvement and Behcet’S Syndrome: Does Bipolar Disorder Represent a Clinical Feature of the Disease?
Rosaria Talarico¹, Elena Elefante², Laura Palagini³, Anna d'Ascanio⁴, Chiara Stagnaro⁴, Chiara Tani⁴, Chiara Baldini⁴, Rossella Neri¹ and Marta Mosca⁴, ¹Rheumatology Unit, University of Pisa, PISA, Italy, ²RHEUMATOLOGY UNIT, University of Pisa, Pisa, Italy, ³Psychiatric Unit, University, PISA, Italy, ⁴Rheumatology Unit, University of Pisa, Pisa, Italy
Background/Purpose: Frequency of psychiatric disorders in Behçet’s syndrome (BS) is a debated issue: while some experts attribute their presence to the chronicity of the illness,…
Abstract Number: 2979 • 2016 ACR/ARHP Annual Meeting
a Systematic Literature Review on the Treatment of Skin, Mucosa and Joint Involvement of BehçEt’s Syndrome Informing the Eular Recommendations for the Management of BehçEt’s Syndrome
Pietro Leccese¹, Yesim Ozguler², Robin Christensen³, Sinem Nihal Esatoglu⁴, Dongsik Bang⁵, Bahram Bodaghi⁶, Aykut Ferhat Celik⁷, Farida Fortune⁸, Julien Gaudric⁹, Ahmet Gul¹⁰, Ina Kotter¹¹, Alfred Mahr¹², Robert J Moots¹³, Ignazio Olivieri¹⁴, Jutta Richter¹⁵, David Saadoun¹⁶, Carlo Salvarani¹⁷, Frances Scuderi¹⁸, PETROS P SFIKAKIS¹⁹, Aksel Siva²⁰, Miles Stanford²¹, Ilknur Tugal-tutkun²², Richard West²³, Sebahattin Yurdakul², Hasan Yazici² and Gulen Hatemi², ¹Rheumatology, Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Matera, Italy, Matera, Italy, ²Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³The Parker instutute, RC, Copenhagen, Denmark, ⁴Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁵Department of Dermatology, Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea, Seoul, Korea, The Democratic People's Republic of, ⁶Ophthalmology, Pierre and Marie Curie University - Paris 6 Paris, France, Paris, France, ⁷Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey, ⁸Dental Institute, Barts and The London NHS Trust, London, United Kingdom, ⁹Department of Vascular surgery GHPS, Paris, France, ¹⁰Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ¹¹Internal Medicine, Robert-Bosch-Hospital, Stuttgart, Germany, ¹²Hospital Saint-Louis, Paris, France, ¹³Academic Rheumatology Unit, University of Liverpool, Liverpool, United Kingdom, ¹⁴U.O. Reumatologia, A.O. Ospedale San Carlo, Potenza, Italy, ¹⁵Tubingen University, Tubingen, Germany, ¹⁶Department of Internal Medicine and Clinical Immunology, AP-HP Pitié-Salpêtrière Hospital, Paris, France, ¹⁷Rheumatology Unit, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ¹⁸Patient partner, Catania, Italy, ¹⁹First Department of Propedeutic Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, ²⁰Department of Neurology, Istanbul University, Cerrahpasa Medical Faculty, Department of Neurology, Istanbul, Turkey, ²¹Ophthalmology, Guy's and St. Thomas' Hospital, London, United Kingdom, ²²Department of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ²³Patient partner, London, United Kingdom
A Systematic Literature Review on the Treatment of Skin, Mucosa and Joint Involvement of Behçet’s Syndrome Informing the Eular Recommendations for the Management of Behçet’s…
Abstract Number: 2980 • 2016 ACR/ARHP Annual Meeting
Inflammation As an Under-Recognized Cause of Ascending Aortic Aneurysms: A Single-Center Clinical and Pathological Study of 53 Cases over 6 Years
Tariq Al-Araimi¹ and Arthur Bookman², ¹Department of Medicine, Toronto, ON, Canada, ²Division of Rheumatology, University Health Network, University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada
Background/Purpose: This study is aimed at estimating the prevalence of inflammatory ascending aneurysms, describing clinical and histopathological findings, and assessing whether appropriate follow-up was arranged…
Abstract Number: 2981 • 2016 ACR/ARHP Annual Meeting
Prospective Cohort of Surgically-Diagnosed Aortitis at the Ottawa Hospital
Kyle Walker¹, Munir Boodhwani² and Nataliya Milman³, ¹University of Ottawa Department of Medicine, Ottawa, ON, Canada, ²Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, ON, Canada, ³University of Ottawa Department of Medicine, University of Ottawa Division of Rheumatology, Ottawa, ON, Canada
Background/Purpose: Idiopathic Aortitis (IA) is poorly defined, with no specific criteria for its classification or diagnosis, except for presence of aortic inflammation and the absence…
Abstract Number: 2982 • 2016 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Inhibitors and the Risk of Malignancy in the Treatment of Juvenile Idiopathic Arthritis
Timothy Beukelman¹, Fenglong Xie², Lang Chen², Daniel Horton³, James D. Lewis⁴, Ronac Mamtani⁴, Melissa Mannion⁵, Kenneth G. Saag⁶, Jie Zhang⁷ and Jeffrey R. Curtis⁶, ¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Pediatrics, University of Alabama at Birmingham, Birmingham, AL, ⁶Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Epidemilogy, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The possible association between tumor necrosis factor inhibitors (TNFi) in the treatment of juvenile idiopathic arthritis (JIA) and an increased risk of malignancy remains…
Abstract Number: 2983 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, or Adalimumab in Patients with Active Psoriatic Arthritis and an Inadequate Response to Conventional Synthetic Dmards: A Randomized, Placebo‑Controlled, Phase 3 Trial
Philip J Mease¹, Stephen Hall², Oliver FitzGerald³, Désirée van der Heijde⁴, Joseph F Merola⁵, Francisco Avila-Zapata⁶, Dorata Cieślak⁷, Daniela Graham⁸, Cunshan Wang⁹, Sujatha Menon⁹, Thijs Hendrikx⁸ and Keith Kanik⁹, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Cabrini Health and Monash University, Melbourne, VIC, Australia, ³Department of Rheumatology, St Vincent’s University Hospital and Conway Institute, University College, Dublin, Ireland, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶Centro Multidisciplinario para el Desarrollo Especializado de la Investigacion Clinica en Yucatan S.C.P., Yucatán, Mexico, ⁷Poznan University, Poznan, Poland, ⁸Pfizer Inc, Collegeville, PA, ⁹Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for treatment of psoriatic arthritis (PsA). This study evaluated tofacitinib efficacy and safety vs placebo…
Abstract Number: 2984 • 2016 ACR/ARHP Annual Meeting
Novel Anti-Malarial Drug Derivative Inhibited Type I Interferon Production and Autoimmune Inflammation through Inhibition of CGAS-Sting Pathway in Trex1-/- Mouse
Jie An¹, Joshua Woodward², Mark Minie³, Xizhang Sun⁴, Lena Tanaka¹, Yufeng Peng¹, Jessica Snyder⁴, Tomikazu Sasaki⁵ and Keith B. Elkon⁶, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Microbiology, University of Washington, Seattle, WA, ³Department of Bioengineering, University of Washington, Seattle, WA, ⁴University of Washington, Seattle, WA, ⁵Department of Chemistry, University of Washington, Seattle, WA, ⁶Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Type I interferon, (IFN-I) is strongly implicated in the pathogenesis of SLE as well as rare monogenic ‘interferonopathies’ such as Aicardi-Goutieres Syndrome (AGS) caused…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].